ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
NuclearSteve
(< 20)
Submitted: 12/29/2011 12:49:57 PM :
Start Price:
$1.11
ACAD Score:
+55.37
Article from Zacks Biotech Guy - Jason Napodano - trying a strategy where I set 10% stops on all these and let the winners run.
Recs
portefeuille
(99.81)
Submitted: 12/15/2011 9:16:01 PM :
Start Price:
$1.21
ACAD Score:
+31.28
There are currently 3500 ACAD shares in my "fund" with break-even of around -2.93 USD.
http://caps.fool.com/Blogs/fund-trades/678775.
Recs
zzlangerhans
(99.26)
Submitted: 11/29/2011 11:37:21 PM :
Start Price:
$0.98
ACAD Score:
+72.22
Acadia has now completely retraced last spring's stirrapulated price spike to 3 and may be headed closer to last fall's all-time low of 0.66. 36M in cash now backs a 51M market cap and quarterly burn is hanging around 5M as the clock ticks towards topline data for study 020 of pimavanserin in Parkinson's psychosis in mid-2012. I've faceplanted on many bottom-feeding moonshot picks over the last couple of years (see Hemispheryx, Cel-Sci, Rexahn, and more than a few others), so I wouldn't bet that this is the end of the drop for Acadia. But I do think this will be a stock to watch closely as phase III data approaches. As for the results? The prior failure of pimavanserin in two phase III trials for the same indication doesn't bode well.
Recs
BillStacker
(< 20)
Submitted: 5/31/2011 12:40:14 PM :
Start Price:
$1.94
ACAD Score:
-7.44
I expect much better results from the next round of phase 3 testing based on their revised methodologies. When those results are published you will see this stock double in anticipation of FDA approval.
Recs
tcoss
(< 20)
Submitted: 4/28/2011 10:26:03 PM :
Start Price:
$2.98
ACAD Score:
-38.28
I do have my worries about this pick. They do have plenty of cash and a phase III trials in the works. Really this is a bet on the phase III trials.
Recs
drmanand
(< 20)
Submitted: 6/17/2010 8:25:07 PM :
Start Price:
$1.11
ACAD Score:
+39.27
Has very important nitch new medications.
a strong buy.
Recs
Ineedmoney101
(< 20)
Submitted: 9/1/2009 4:12:42 PM :
Start Price:
$1.30
ACAD Score:
+16.89
All i can say is wow. Pharmecueticals are supposed to go up during this month, this is a great company with amazing financial statements, it didn't beat the leading parkinsis psychosis drug, big deal, but not this big of a deal. I think i'm gonna need to load up on this one for the rebound.
Recs
SmallPimpin
(95.17)
Submitted: 9/1/2009 1:00:17 PM :
Start Price:
$1.95
ACAD Score:
-42.32
Mmm...biopharmaceuticals...
Recs
BruceInToronto
(42.67)
Submitted: 8/25/2009 4:15:06 PM :
Start Price:
$6.08
ACAD Score:
-101.67
Phase three drug approval coming soon
Recs
tensaibakabon
(< 20)
Submitted: 8/12/2009 2:57:31 AM :
Start Price:
$1.85
ACAD Score:
-34.70
Phase 3 due anytime and as per the CEO will be topline results
Recs
Brian7992
(< 20)
Submitted: 7/29/2009 6:37:35 AM :
Start Price:
$4.24
ACAD Score:
-96.09
End of Phase III Clinical Trials and talk of Buy Out should drive this stock to new highs in the comming weeks! I see a 400 to 800% rise in price.
Recs
Brihally
(82.25)
Submitted: 6/16/2008 7:10:25 PM :
Start Price:
$4.52
ACAD Score:
-61.94
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.
Recs
bobby410
(< 20)
Submitted: 12/4/2007 5:35:41 PM :
Start Price:
$11.63
ACAD Score:
-79.68
Have a friend who works there, & things are looking very very good.
Recs
sdpowell
(57.92)
Submitted: 10/29/2007 6:44:10 PM :
Start Price:
$15.16
ACAD Score:
-79.86
huge potential for the drugs they offer, good chance of being acquired by a large company too
Recs
razormd
(26.66)
Submitted: 10/17/2007 12:58:27 PM :
Start Price:
$15.25
ACAD Score:
-79.91
...I accidently had this listed as an "underperform"...I'm now correcting that...as I posted previously they have a lot of cash on hand...Allergan collaboration looks promising...pimavanserin moving steadily along...any drug development company is risky but this one looks worthy of a few seculative dollars
Recs
BRKLMB
(< 20)
Submitted: 8/22/2007 12:50:18 PM :
Start Price:
$14.93
ACAD Score:
-84.96
Upside based on likely pharma partnership before end of 2007
Recs
MCvest
(< 20)
Submitted: 7/12/2007 9:04:16 PM :
Start Price:
$13.50
ACAD Score:
-78.17
ACAD (VERY speculative, very up and down stock but I am betting on drug phase approval sending this stock up 100%)
Recs
EmpireBldr99
(69.95)
Submitted: 6/15/2007 11:23:30 AM :
Start Price:
$15.26
ACAD Score:
-80.40
Pure spec
Recs
mastiff5
(64.40)
Submitted: 6/10/2007 10:29:07 PM :
Start Price:
$14.49
ACAD Score:
-81.69
good time for pharmsss.
Recs
HaggardFrodo
(< 20)
Submitted: 4/19/2007 4:46:20 PM :
Start Price:
$14.86
ACAD Score:
-83.72
Low market cap related to potential for drug candidates. Requires patience - buy on dips
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 28 : 1 2 Next »